Skip to main content
TipRanks
Go Ultimate75% OFF

Mustang Bio (MBIO) AI Stock Analysis

1,601 Followers
MBIO

Mustang Bio

(NASDAQ:MBIO)

Select Model
Rating:40Underperform
Price Target:$0.66â–²(57.01% Upside)
Action:downgraded
Date:05/09/26

Mustang Bio's score is driven primarily by its weak financial performance as a pre-revenue biotech with persistent losses, despite improvements in cost control and a debt-free balance sheet. The stock is in a clear downtrend with bearish technicals, and traditional valuation metrics offer no support. While the company has made strides toward financial stability, significant uncertainty remains, resulting in a low overall score.

Positive Factors
Low leverage / stronger balance sheetZero reported debt and a recovery of stockholders’ equity materially reduce solvency risk and interest burden. This improves financial flexibility to fund clinical programs or negotiate collaborations, extending runway and lowering default risk versus prior periods.
Negative Factors
Pre-revenue profileWith no product revenue, the company lacks recurring cash inflows to fund operations. Long-term viability therefore depends on future clinical success and external financing, making operational continuity vulnerable to trial setbacks or capital-market conditions.

Mustang Bio (MBIO) vs. SPDR S&P 500 ETF (SPY)

-80%-60%-40%-20%0%20%MBIO-65.77%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$2.84M
Dividend Yield
―
Average Volume (3M)
32.28K
Price to Earnings (P/E)
-0.8
Beta (1Y)
0.76
Revenue Growth
―
EPS Growth
59.14%
Country
US
Employees
4
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Mustang Bio Business Overview & Revenue Model

Company Description

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen...

How the Company Makes Money

Mustang Bio is a clinical-stage company and, as such, does not have a broadly established, recurring product-revenue base from commercialized therapies. The company has historically funded operations primarily through capital raising (e.g., equity fi...

Mustang Bio Financial Statement Overview

Summary

Mustang Bio has no revenue and continues to report net losses, though losses have narrowed significantly. The balance sheet is debt-free with positive equity, providing a modest cushion. Operating cash flow remains negative but improving. Overall financial health is weak but showing progress, typical of a developmental-stage biotech.

Income Statement

30Negative

Balance Sheet

65Positive

Cash Flow

35Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue000000
Gross Profit0-41.00K0-2.23M-3.03M-2.31M
EBITDA-3.53M-1.88M-14.92M-48.06M-71.14M-64.05M
Net Income-3.53M-1.92M-15.75M-51.60M-77.53M-66.37M
Balance Sheet
Total Assets14.68M17.59M9.31M17.74M92.42M125.17M
Cash, Cash Equivalents and Short-Term Investments14.28M17.27M6.84M6.23M75.66M109.62M
Total Debt00878.00K2.50M31.38M2.03M
Total Liabilities8.10M8.06M13.18M17.62M46.15M12.77M
Stockholders Equity6.59M9.53M-3.87M123.00K46.27M112.40M
Cash Flow
Free Cash Flow-4.57M-5.26M-11.41M-49.59M-68.14M-59.03M
Operating Cash Flow-4.57M-5.26M-11.41M-49.48M-65.07M-53.67M
Investing Cash Flow01.17M05.89M-2.95M-5.37M
Financing Cash Flow-139.00K14.53M11.27M-26.08M34.06M70.85M

Mustang Bio Technical Analysis

Technical Analysis SentimentNeutral
Last Price0.42

Price Trends

50DMA0.44Negative
100DMA0.53Negative
200DMA0.66Negative

Market Momentum

MACD-0.00Negative
RSI50.54Neutral
STOCH51.99Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MBIO, the sentiment is Neutral. The current price of 0.42 is above the 20-day moving average (MA) of 0.40, below the 50-day MA of 0.44, and below the 200-day MA of 0.66, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 50.54 is Neutral, neither overbought nor oversold. The STOCH value of 51.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MBIO.

Mustang Bio Risk Analysis

Mustang Bio disclosed 65 risk factors in its most recent earnings report. Mustang Bio reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.If we are unable to maintain compliance with all applicable continued listing requirements and standards of Nasdaq, our common stock may be delisted from Nasdaq.Q3, 2024
2.The market price for our common stock has been volatile and may continue to fluctuate or may decline significantly in the future.Q3, 2024
3.If we are unable to maintain compliance with all applicable continued listing requirements and standards of Nasdaq, our common stock may be delisted from Nasdaq.Q2, 2024

Mustang Bio Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

MBIO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
BOLTBOLT47Neutral$11.71M-0.42-154.11%―-51.28%32.80%
ACXPACXP45Neutral$5.82M-0.34-116.60%――72.95%
LYRALYRA41Neutral$337.23K-0.01455.31%―-74.05%73.08%
SLXNSLXN41Neutral$1.29M-0.00-895.97%――36.44%
MBIOMBIO40Underperform$3.20M-0.82-43.76%――59.14%
XTLBXTLB39Underperform$7.81M-0.54-269.02%―――

* Healthcare Sector Average

Performance Comparison

-100%-50%0%50%MBIOXTLBLYRABOLTSLXNACXPDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
MBIO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
MBIOMustang Bio0.42-0.74-63.71%
XTLBXTL Biopharmaceuticals Ltd. Sponsored ADR1.60-2.04-56.04%
LYRALyra Therapeutics, Inc.0.19-3.55-94.92%
BOLTBolt Biotherapeutics, Inc.6.081.5734.81%
SLXNSilexion Therapeutics Corp1.98-617.22-99.68%
ACXPAcurx Pharmaceuticals Llc0.96-3.26-77.25%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: May 09, 2026